These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1608904)

  • 21. [Cefuroxime axetil].
    Matsumoto F; Oizumi K
    Jpn J Antibiot; 1988 Sep; 41(9):1181-93. PubMed ID: 3071614
    [No Abstract]   [Full Text] [Related]  

  • 22. Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.
    Perry CM; Brogden RN
    Drugs; 1996 Jul; 52(1):125-58. PubMed ID: 8799689
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stability of cefuroxime axetil in suspensions.
    Pramar Y; Das Gupta V; Bethea C; Zerai T
    J Clin Pharm Ther; 1991 Oct; 16(5):341-4. PubMed ID: 1752913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of malnutrition on the pharmacokinetics of cefuroxime axetil in young rats.
    González-Hernández I; Jung-Cook H; Sotelo A
    J Pharm Pharm Sci; 2008; 11(1):9-21. PubMed ID: 18445361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Esters of cephalosporins. Part III. Separation and properties of the R and S isomers of the 1-acetoxyethyl ester of cefuroxime.
    Oszczapowicz I; Małafiej E; Horoszewicz-Małafiej A; Szelachowska M; Kuklewicz C; Sierańska E
    Acta Pol Pharm; 1995; 52(6):471-6. PubMed ID: 8960265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of stability of cefuroxime axetil in solid state.
    Zajac M; Jelińska A; Dobrowolski L; Oszczapowicz I
    J Pharm Biomed Anal; 2003 Aug; 32(6):1181-7. PubMed ID: 12907262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Model simulation of a single oral dose of cefuroxime axetil and the related in-vitro kill kinetics against four bacterial species.
    Silley P; Monsey D; Harris AM
    J Antimicrob Chemother; 1990 Jan; 25(1):83-90. PubMed ID: 2180892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phosphate binders do not reduce bioavailability of oral cefuroxime-axetil in patients on peritoneal dialysis treatment.
    Brink HS; Huisman RM; Geerlings W; de Jong PE
    Adv Perit Dial; 1994; 10():179-82. PubMed ID: 7999822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [In-vitro activity of cefuroxime-axetil against pathogens of bacterial infections of the respiratory tract].
    Kayser FH; Bille J
    Schweiz Rundsch Med Prax; 1990 Nov; 79(45):1383-6. PubMed ID: 2080392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transport mechanisms responsible for the absorption of loracarbef, cefixime, and cefuroxime axetil into human intestinal Caco-2 cells.
    Dantzig AH; Duckworth DC; Tabas LB
    Biochim Biophys Acta; 1994 Apr; 1191(1):7-13. PubMed ID: 8155686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of cefuroxime axetil in patients with normal and impaired renal function.
    Konishi K; Suzuki H; Hayashi M; Saruta T
    J Antimicrob Chemother; 1993 Mar; 31(3):413-20. PubMed ID: 8486575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cefuroxime axetil.
    Emmerson AM
    J Antimicrob Chemother; 1988 Aug; 22(2):101-4. PubMed ID: 3053551
    [No Abstract]   [Full Text] [Related]  

  • 33. Bioequivalence evaluation of 2 brands of cefuroxime axetil 250 mg tablets in healthy human volunteers.
    Pistos C; Michalea S; Kalovidouris M; Kontopoulos G; Georgarakis M
    Int J Clin Pharmacol Ther; 2004 Jul; 42(7):367-72. PubMed ID: 15605688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cefuroxime axetil (Zinnat)--laboratory and clinical study].
    Vyhnánek F; Hejzlar M; Procházka M; Pellar T; St'astná L; Silarová J; Kittnar E; Vedral T
    Rozhl Chir; 1990 Oct; 69(10):668-73. PubMed ID: 2263996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concentration of cefuroxime in serum and middle ear effusion after single dose treatment with cefuroxime axetil.
    Haddad J; Isaacson G; Respler DS; Hart RW; Yilmaz HM; Collins JJ; Bluestone CD
    Pediatr Infect Dis J; 1991 Apr; 10(4):294-8. PubMed ID: 2062625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative investigations on the bioavailability of cefuroxime axetil.
    Kees F; Lukassek U; Naber KG; Grobecker H
    Arzneimittelforschung; 1991 Aug; 41(8):843-6. PubMed ID: 1781808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cefuroxime axetil.
    Med Lett Drugs Ther; 1988 Jun; 30(767):57-9. PubMed ID: 3367854
    [No Abstract]   [Full Text] [Related]  

  • 38. Bronchoalveolar distribution of cefuroxime axetil and in-vitro efficacy of observed concentrations against respiratory pathogens.
    Baldwin DR; Andrews JM; Wise R; Honeybourne D
    J Antimicrob Chemother; 1992 Sep; 30(3):377-85. PubMed ID: 1452503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Segmental differences in drug permeability, esterase activity and ketone reductase activity in the albino rabbit intestine.
    Narawane M; Podder SK; Bundgaard H; Lee VH
    J Drug Target; 1993; 1(1):29-39. PubMed ID: 7915178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [New special agents registered in Austria. Zinnat (cefuroxime axetil, glaxo)].
    Gartler W
    Wien Klin Wochenschr; 1991; 103(10):306-12. PubMed ID: 1858381
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.